2 Outperforming Biotech Stocks to Examine on Covid-19 Vaccine Updates

These undervalued health care companies have outperformed the S&P 500 so far this year

Author's Avatar
Sep 21, 2021
  • Pfizer and BioNTech recently announced their Covid-19 vaccine is safe for school-age children.
  • Johnson & Johnson also provided an update on their booster shot.
  • Regeneron and BeiGene have outperformed the S&P 500 year to date.
Article's Main Image

With recent updates from Pfizer Inc. (

PFE, Financial) and BioNTech SE (BNTX, Financial) regarding the effectiveness of their Covid-19 vaccine among children ages 5 to 11 and Johnson & Johnson’s (JNJ, Financial) booster shot announcement, consumers and investors alike are continuing to carefully watch the health care space.

As a result of this progress, value opportunities may be found among health care companies that outperformed the Standard & Poor’s 500 Index. As of Sept. 21, the GuruFocus All-in-One Screener, a Premium feature, found several stocks that with a market cap over $5 billion that had a higher return relative to the index for the period. It also looked at stocks with GF Value ranging from significantly undervalued to fairly valued.

Based on these criteria, health care stocks that outperformed the S&P 500 by at least 15% year to date are Regeneron Pharmaceuticals Inc. (

REGN, Financial) and BeiGene Ltd. (BGNE, Financial). The S&P 500 Index has gained around 18.45% over the same period.

Regeneron Pharmaceuticals

Having climbed nearly 35% year to date, Regeneron Pharmaceuticals (

REGN, Financial) has a $69.51 billion market cap; its shares were trading around $649.94 on Tuesday with a price-earnings ratio of 11.66, a price-book ratio of 4.59 and a price-sales ratio of 5.85.


The GF Value Line indicates that the stock is modestly undervalued currently based on historical ratios, past performance and future earnings projections.


The Tarrytown, New York-based biotech company has a GuruFocus financial strength rating of 7 out of 10. In addition to adequate interest coverage, Regeneron is supported by a robust Altman Z-Score of 9.69 that implies it is in good standing even though assets are building up at a faster rate than revenue is growing. The return on invested capital also overshadows the weighted average cost of capital, suggesting the company is able to create value as it grows.

Regeneron’s profitability scored an 8 out of 10 rating, driven by operating margin expansion, strong returns on equity, assets and capital that outperform a majority of competitors and a moderate Piotroski F-Score of 6, meaning conditions are typical for a stable company. The company also has a predictability rank of one out of five stars. According to GuruFocus, companies with this rank gain an average of 1.1% annually over a 10-year period.

Of the gurus invested in Regeneron as of the end of the second quarter, the

Vanguard Health Care Fund (Trades, Portfolio) has the largest stake with 2.4% of its outstanding shares. Other top guru shareholders include Catherine Wood (Trades, Portfolio), Bill Nygren (Trades, Portfolio), Steven Cohen (Trades, Portfolio), Pioneer Investments, Tom Gayner (Trades, Portfolio), Jeremy Grantham (Trades, Portfolio), Louis Moore Bacon (Trades, Portfolio) and Ray Dalio (Trades, Portfolio).


With a gain of over 50% year to date, BeiGene (

BGNE, Financial) has a market cap of $37.7 billion; its shares were trading around $391.41 on Tuesdaywith a price-book ratio of 10.06 and a price-sales ratio of 39.03.


According to the GF Value Line, the stock is fairly valued currently.


The Chinese biotech company, which specializes in developing drugs to treat cancer, has a financial strength rating of 6 out of 10 from GuruFocus. As a result of issuing approximately $422.9 million in new long-term debt over the past three years, it has poor interest coverage. The high Altman Z-Score of 11.16, however, suggests it is in good standing even though the Sloan ratio is indicative of poor earnings quality.

The company’s profitability did not fare as well, scoring a 3 out of 10 rating even though the operating margin is expanding and its negative returns outperform over half of its industry peers. BeiGene also has a moderate Piotroski F-Score of 5, but has recorded losses in operating income and declining revenue per share over the past several years.

With a 4.62% stake,

Baillie Gifford (Trades, Portfolio) is the company’s largest guru shareholder. PRIMECAP Management (Trades, Portfolio), Vanguard’s Health Care Fund, Pioneer Investments, Dalio, the iShares MSCI ACWI ex. U.S. ETF, Ken Fisher (Trades, Portfolio) and Lee Ainslie (Trades, Portfolio) also own the stock.

Also check out:


I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours. Click for the complete disclosure
0 / 5 (0 votes)